{"url_path":"/sec/ltrn/8-k/2026-06-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-026696-index.html","accession_number":"0001493152-26-026696","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-026696-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":97,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Exhibit\nDescription**\n\n \n \n \n\n99.1\n \n[Presentation relating to June 1, 2026 discussions regarding the Harmonic™ LP-300 Phase 2 clinical trial.](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nLantern\nPharma Inc.,\n\n \nA\nDelaware Corporation\n\n \n \n \n\nDated:\nJune 1, 2026\nBy:\n*/s/\nDavid R. Margrave*\n\n \n \nDavid\nR. Margrave, Chief Financial Officer\n\n \n\n3"}